News
CAR T-cell therapy found safe, effective for HIV-associated lymphoma
Two HIV-positive patients with chemotherapy-refractory, high-grade B-cell lymphoma achieved complete remission with anti-CD19 CAR T-cell therapy,...
News
Staging PET/CT better defines extent of mantle cell lymphoma
This type of imaging altered stage and management in nearly one-fifth of cases.
News
Tamoxifen benefit in lower-risk breast cancer varies by intrinsic subtype
Among postmenopausal patients with node-negative, ER-positive breast cancer, significant benefit of adjuvant tamoxifen over no endocrine therapy...
News
Center’s experience casts doubt on clinical utility of NGS
Testing commonly revealed actionable aberrations, but only about 1 in 10 usable tests led to a change in patient management, raising questions...
News
Bevacizumab-erlotinib combo falls short in EGFR-mutant advanced NSCLC
Adding the antiangiogenic agent to the EGFR tyrosine kinase inhibitor did not significantly prolong PFS and was associated with more grade 3 or...
News
CVD risk after breast cancer: Adipose distribution trumps BMI
The more fat that breast cancer survivors had in the visceral compartment or intramuscular compartment, the higher their CVD risk, regardless of...
News
Benefit of chemo + RT for high-risk endometrial cancer increases with time
With longer follow-up, analyses showed emergence of a significant overall survival benefit of adjuvant chemoradiotherapy over radiotherapy alone,...
News
Real-world data for immunotherapy-treated NSCLC found robust
Endpoints seen among patients treated with PD-1/PD-L1 inhibitors in real-world settings were consistent within data sets and similar to those...
News
Erdafitinib is efficacious in FGFR-altered urothelial carcinoma
The drug had good antitumor activity in the pretreated trial population, despite high rates of grade 3 or worse treatment-related adverse events...
News
Durvalumab fails to advance in pancreatic cancer
Durvalumab, with or without tremelimumab, was safe and well tolerated in patients with recurrent or metastatic PDAC, but response rates did not...
News
Hurricanes delay RT, worsening survival of NSCLC
Patients undergoing definitive radiotherapy during a declaration of hurricane disaster had a 21-day longer radiation treatment duration and were...
News
Ibrutinib-venetoclax found highly active in hard-to-treat CLL
Trial results suggest the two drugs may have synergistic efficacy when used together, and raise the possibility of achieving MRD negativity with...
News
Atezolizumab combo in first-line NSCLC misses cost-effectiveness mark
The incremental cost‐effectiveness ratio of ABCP as compared with BCP or with CP – more than $500,000 per QALY – far exceeded the conventional...
News
Gaps in patient-provider survivorship communication persist
Over a recent 5-year period, there was little change in the percentages of patients who reported not having any detailed discussion with providers...
News
Comorbidities drive excess mortality after breast cancer diagnosis in childhood cancer survivors
A retrospective analysis found that, among matched breast cancer patients, childhood cancer survivors had a more than doubling of all-cause...